What's new in genitourinary pathology 2023: WHO 5th edition updates for urinary tract, prostate, testis, and penis

Area of Science:

• Urologic Oncology
• Pathology
• Genitourinary Tumors

Background:

• The World Health Organization (WHO) Classification of Urinary and Male Genital Tumours is a critical reference for diagnosing and managing these cancers.
• The 5th edition (2022) represents a major update, incorporating recent advances in molecular pathology and clinical understanding.
• Previous updates have significantly impacted diagnostic criteria and therapeutic strategies in urologic oncology.

Purpose of the Study:

• To summarize the key changes introduced in the 5th edition of the WHO Classification of Urinary and Male Genital Tumours (2022).
• To highlight revisions pertaining to tumors of the bladder, prostate, testis, and penis.
• To provide urologists with a concise overview of updates relevant to daily clinical practice.

Main Methods:

• Review and synthesis of the 5th edition (2022) WHO Classification of Urinary and Male Genital Tumours.
• Focus on specific changes related to bladder, prostate, testis, and penis tumors.
• Comparison with previous classifications to identify significant revisions.

Main Results:

• The 5th edition WHO Classification (2022) introduces substantial modifications to the categorization and terminology of genitourinary tumors.
• Notable changes affect the classification of bladder, prostate, testis, and penis neoplasms, impacting diagnostic criteria.
• Revisions reflect advancements in molecular diagnostics and a refined understanding of tumor biology.

Conclusions:

• The 5th edition WHO Classification (2022) necessitates an update in urologic practice regarding the diagnosis and management of urinary and male genital tumors.
• Understanding these revisions is crucial for accurate pathological assessment and appropriate clinical decision-making.
• This summary serves as a guide to the most impactful changes for clinicians.